Definiens  The tissue phenomics company

AstraZeneca and its research and development division, MedImmune, acquired Definiens

Definiens’ technology provides detailed tissue biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information, an approach known as Tissue Phenomics. The system reportedly improves the search for biomarkers in cancer tissues by measuring important variables within the sample, such as the location, identity and interaction between key constituents.


Digital Health

Case facts




Exit June 2014

Involved Team